Pharmacodynamics of investigational pre-beta HDL-mimicking agent
Dr. Eralp Bellibas (The Medicines Company, Parsippany, NJ, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs Dr. Eralp Bellibas shares pharmacokinetic and pharmacodynamic data of the apoA1-Milano-POPC (MDCO216) that was developed to mimic pre-beta HDL molecules, which was more potent at increasing cholesterol efflux in CAD patients than in healthy volunteers.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: